HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.

Abstract
Diffuse large B cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma. While the initial treatment strategy is highly effective, relapse occurs in 40% of cases. Histone deacetylase inhibitors (HDACi) are a promising class of anti-cancer drugs but their single agent efficacy against relapsed DLBCL has been variable, ranging from few complete/partial responses to some stable disease. However, most patients showed no response to HDACi monotherapy for unknown reasons. Here we show that sensitivity and resistance to the hydroxamate HDACi, PXD101, can be modeled in DLBCL cell lines. Sensitivity is characterized by G 2/M arrest and apoptosis and resistance by reversible G 1 growth arrest. These responses to PXD101 are independent of several negative prognostic indicators such as DLBCL subtype, BCL2 and MYC co-expression, and p53 mutation, suggesting that HDACi might be used effectively against highly aggressive DLBCL tumors if they are combined with other therapeutics that overcome HDACi resistance. Our investigation of mechanisms underlying HDACi resistance showed that cyclin-dependent kinase inhibitors (CKIs), p21 and p27, are upregulated by PXD101 in a sustained fashion in resistant cell lines concomitant with decreased activity of the cyclin E/cdk2 complex and decreased Rb phosphorylation. PXD101 treatment results in increased association of CKI with the cyclin E/cdk2 complex in resistant cell lines but not in a sensitive line, indicating that the CKIs play a key role in G 1 arrest. The results suggest several treatment strategies that might increase the efficacy of HDACi against aggressive DLBCL.
AuthorsAna A Tula-Sanchez, Aaron P Havas, Peter J Alonge, Mary E Klein, Samantha R Doctor, William Pinkston, Betty J Glinsmann-Gibson, Lisa M Rimsza, Catharine L Smith
JournalCancer biology & therapy (Cancer Biol Ther) Vol. 14 Issue 10 Pg. 949-61 (Oct 01 2013) ISSN: 1555-8576 [Electronic] United States
PMID23982416 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • MYC protein, human
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-myc
  • Retinoblastoma Protein
  • Sulfonamides
  • Cyclin-Dependent Kinase Inhibitor p27
  • belinostat
Topics
  • Antineoplastic Agents (pharmacology)
  • Apoptosis
  • Cell Line, Tumor (drug effects)
  • Cell Proliferation (drug effects)
  • Cyclin-Dependent Kinase Inhibitor p21 (physiology)
  • Cyclin-Dependent Kinase Inhibitor p27 (physiology)
  • Drug Resistance, Neoplasm
  • Drug Screening Assays, Antitumor
  • G2 Phase Cell Cycle Checkpoints
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Histone Deacetylase Inhibitors (pharmacology)
  • Humans
  • Hydroxamic Acids (pharmacology)
  • Inhibitory Concentration 50
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, metabolism)
  • Phosphorylation
  • Protein Processing, Post-Translational (drug effects)
  • Proto-Oncogene Proteins c-bcl-2 (metabolism)
  • Proto-Oncogene Proteins c-myc (metabolism)
  • Retinoblastoma Protein (metabolism)
  • Sulfonamides (pharmacology)
  • Up-Regulation (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: